Pendistrep

Quick links to important sections

Pendistrep

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pendistrep

Quick Facts

Property Description
Active Ingredients Benzylpenicillin (Penicillin G), Dihydrostreptomycin
Form Injectable Suspension
Pharmacological Class Combination Antibiotic (Beta-lactam and Aminoglycoside)
General Purpose Management of bacterial infections in livestock
Origin Semi-synthetic

What is Pendistrep? Definition and Pharmacological Identity

Pendistrep is a specialized, prescription-only antimicrobial preparation classified as a combination antibiotic, designated primarily for veterinary use. This agent is structurally defined by the fixed pairing of two potent active ingredients from distinct pharmacological classes, a strategy used for optimizing antimicrobial effectiveness. The product is categorized as a broad-spectrum antimicrobial because it strategically combines a beta-lactam agent with an aminoglycoside to achieve coverage against a wide range of common bacterial pathogens. The Benzylpenicillin component belongs to the Penicillin class, and the Dihydrostreptomycin component is an Aminoglycoside antibiotic, a grouping characterized by its distinct mechanism of inhibiting protein synthesis.

Composition, Type, and Formulation

The core composition of Pendistrep consists of the active ingredients Benzylpenicillin and Dihydrostreptomycin, formulated as an injectable suspension. The combination, often referred to by the generic term Pen/Strep, represents a classic, time-tested dual-agent approach. Benzylpenicillin is a semi-synthetic antibiotic derived from fungal sources, while Dihydrostreptomycin is derived from the related compound streptomycin. This specific pharmaceutical form is an injectable suspension—a liquid preparation designed exclusively for parenteral administration. Unlike single-drug solutions, this combination provides the immediate availability of two distinct bactericidal agents, ensuring a rapid systemic response against susceptible organisms in scenarios like widespread systemic infection.

General Purpose and Benefit of Dual-Action Antibiotics

The general purpose of Pendistrep is to provide a potent, comprehensive response for managing widespread or localized bacterial infections through its dual-action mechanism. This preparation is utilized to effectively eliminate susceptible harmful bacteria, functioning as a primary intervention against bacterial threats in livestock, for instance, in cases involving respiratory or gastrointestinal infections. The inherent benefit of combining these two active agents is the synergistic effect, where the combined efficacy exceeds their individual actions. This bactericidal approach is characterized by targeting bacteria simultaneously via both cell wall structure and internal protein synthesis pathways.

Regulatory References

  1. WHO AWaRe Antibiotics Access Group

What side effects are possible with Pendistrep?

Possible Side Effects and Safety Information

Pendistrep, a combination of Benzylpenicillin (a penicillin) and Dihydrostreptomycin (an aminoglycoside), has a documented safety profile reflecting the risks associated with both pharmacological classes, as formally classified in government regulatory documents.

Adverse Reaction Scope and Classification

Adverse reactions are classified by frequency and involved System-Organ Classes (SOC). Key SOC categories include Immune System Disorders, Ear and Labyrinth Disorders, and Renal and Urinary Disorders.

  • Common Reactions may include mild gastrointestinal disturbances and local reactions at the injection site.
  • Serious Adverse Reactions, classified as rare or uncommon, include immediate, life-threatening Anaphylactic Shock (associated with Benzylpenicillin) and potentially irreversible Ototoxicity (vestibular damage or permanent deafness) and Acute Renal Failure (Nephrotoxicity), primarily linked to Dihydrostreptomycin.

Population and Duration-Related Safety Constraints

The risk of severe neurotoxic reactions and kidney damage is officially documented as being higher in specific populations. The medicine is contraindicated in individuals with a known history of allergy to penicillins or aminoglycosides. Furthermore, there is a heightened risk for patients with pre-existing renal impairment and for older adults due to the potential for drug accumulation. The risk of Ototoxicity is explicitly noted in official labeling as being cumulatively related to the total dose and duration of exposure, necessitating careful observation of renal function during treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of the combination antibiotic Pendistrep is associated with severe, systemic toxicities derived from both active components. Exposure to very high concentrations, often exacerbated by pre-existing renal impairment, significantly increases the risk profile and necessitates immediate medical intervention.

Documented Manifestations and Severe Outcomes

The official regulatory profile documents two primary areas of severe risk. The Benzylpenicillin component can cause Central Nervous System (CNS) excitation, presenting as seizures, myoclonus, or encephalopathy. The Dihydrostreptomycin component is associated with nephrotoxicity leading to acute renal failure, and sensory disturbances such as tinnitus and hearing loss, which may become irreversible. A critical, life-threatening manifestation is neuromuscular blockade, which can progress to respiratory depression or paralysis, requiring continuous cardiorespiratory monitoring.

Required Emergency Actions

The appearance of any severe symptom—such as difficulty breathing, seizures, or signs of anaphylactic reaction—mandates that immediate medical attention must be sought, and emergency services contacted. Regulatory guidance confirms that no specific antidote is known for the penicillin-related neurotoxicity. However, management includes general symptomatic and supportive treatment, fluid and electrolyte monitoring, and the potential use of calcium salts as an intervention for neuromuscular effects. Hospital observation is required to address potential life-threatening complications.

Therapeutic Uses of Pendistrep

What Pendistrep Treats: Main Uses and Benefits

Pendistrep is commonly used for managing systemic bacterial infections that cause severe, widespread symptomatic patterns, including Septicaemia, Meningitis, and deep-seated diseases like Listeriosis. This use is consistent with the established antimicrobial profiles of its parent components, Penicillin and Dihydrostreptomycin. The support provided by this medication helps address symptoms related to systemic imbalance and acute, pronounced fever, and may be part of symptomatic management during acute episodes.


This combination is commonly used for infections localized to specific organ systems. This includes infections of the respiratory tract (e.g., Pneumonia, Bronchopneumonia), urogenital tract (e.g., Endometritis, Pyelonephritis), and severe conditions affecting the joints and soft tissues (e.g., Navel/Joint Ill). The use of this medication helps address symptom clusters related to acute localized distress, inflammatory states, and functional strain. The dual-action nature is commonly used in mixed infections or when empirical treatment is necessary, providing support in managing infections caused by a diverse array of pathogens.

“The primary goal of using this combination is to provide supportive relief, contributing to easing the overall symptom load associated with complex or undefined bacterial challenges.”

Quick Fact: Support for Key Symptom Management
Systemic Support Helps address fever and generalized listlessness associated with widespread infection.
Localized Comfort Relevant for easing acute distress, pain, and inflammation in affected joints and tissues.
Broad Context Applied in scenarios involving mixed Gram-positive and Gram-negative bacterial challenges.

Eligibility and Restrictions for Use

Pendistrep is an officially regulated Veterinary Medicinal Product (VMP). The eligibility and non-eligibility rules are based on official government regulatory documents for animal health and food safety. No human-specific regulatory profile for this combination drug name is available from authoritative governmental sources.

Populations for Whom Use is Prohibited (Contraindicated)

Classification Population/Condition Regulatory Basis
Absolute Contraindication Animals with a known hypersensitivity (allergy) to penicillins, cephalosporins, or aminoglycosides. Allergy Risk
Absolute Contraindication Animals with diagnosed renal insufficiency or seriously defective renal function. Kidney Impairment
Food Safety Exclusion Horses intended for the human food chain (meat consumption). Withdrawal Period
Food Safety Exclusion Sheep producing milk intended for human consumption. Withdrawal Period

Populations Requiring Restricted or Conditional Use

Classification Population/Condition Restriction/Warning
Conditional Use Animals with known kidney disease. Must be used with care; dosage should not be exceeded.
Conditional Use Pregnant sows and gilts. Use is associated with reports of vulval discharge and potential abortion.

These official regulatory statements define the scope of use by establishing clear lines of exclusion based on severe medical conditions, such as immune hypersensitivity and kidney impairment. Eligibility is further strictly controlled by food chain regulations, prohibiting use in animals intended to produce certain human foodstuffs (meat and milk) to ensure public health standards are met.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information classifies several combinations as either strictly prohibited or requiring specific restriction due to documented interaction patterns. The Benzylpenicillin component's bactericidal effect is subject to pharmacodynamic antagonism by bacteriostatic agents. Consequently, co-administration with classes such as Tetracyclines, Chloramphenicol, Macrolides, and Lincosamides is designated as a contraindicated combination.

The Dihydrostreptomycin component carries a risk of synergistic toxic effects when combined with certain medicinal products. Specifically, concurrent use with Loop Diuretics (e.g., Furosemide or Ethacrynic Acid) is documented to increase the official risk of ototoxicity and nephrotoxicity. Furthermore, this component's neuromuscular blocking activity is potentiated by co-administered Neuromuscular Blocking Agents and some anesthetics.

A pharmacokinetic interaction alters the clearance of the Benzylpenicillin component. Agents like Probenecid and certain Organic Anions interfere with renal tubular secretion, which officially results in increased and prolonged plasma exposure of Benzylpenicillin. Procedural restrictions mandate that the injectable suspension must not be physically mixed with other solutions in the same syringe due to physical incompatibility. The overall interaction risk is heightened in cases of seriously impaired renal function due to reduced clearance and accumulation of Dihydrostreptomycin.

Mechanism of Action

Cell Wall Synthesis Inhibition

This domain involves the action of the penicillin G salts (procaine and benzathine penicillin). These beta-lactam antibiotics engage and inhibit bacterial Penicillin-Binding Proteins (PBPs), which are enzymes crucial for the final stage of peptidoglycan synthesis—the main structural component of the bacterial cell wall. This suppression of cell wall construction in susceptible organisms results in cell lysis and subsequent microbial death.


Protein Biosynthesis Disruption

The second mechanistic domain is mediated by dihydrostreptomycin, an aminoglycoside component. This molecule binds to the 30S ribosomal subunit within the bacterial cell, interfering with the initiation and elongation phases of protein synthesis and causing misreading of the genetic code. This action modifies early molecular steps in protein assembly, leading to the synthesis of non-functional proteins.


Pathway Synergy

The drug engages an amplified mechanism by combining its two active components, which target distinct, non-overlapping pathways within the microbial cell. This additive to synergistic action broadens the spectrum of susceptible pathogens by initiating or suppressing signaling sequences in a wider range of microbes. The physiological consequence is an expanded spectrum of microbial susceptibility, resulting in broad-spectrum microbial inhibition.

Dosage and Administration Information

Pendistrep is a combination antimicrobial administered exclusively as an aqueous suspension for injection. The official administration method is primarily by deep intramuscular (IM) injection, though the subcutaneous (SC) route is an alternative method.

The dosage is strictly based on the target animal's accurate body weight determination. The official high-level rate is 1 mL per 25 kg of bodyweight. This quantity must be administered on a once-daily schedule, which corresponds to 8 mg/kg Procaine Penicillin and 10 mg/kg Dihydrostreptomycin Sulphate.

Procedural Administration Rules

Prior to drawing the dose, the suspension vial must be shaken well to ensure the active ingredients are homogeneously mixed. A critical constraint on administration is the maximum volume allowed at any single injection site, which is species-dependent (e.g., 6 mL for cattle). For doses exceeding this volume, the total amount must be divided and administered across multiple sites. Furthermore, the suspension must not be mixed with any other injectable products in the same syringe. The entire treatment course is restricted to a short-term duration of up to 3 consecutive days, defining the complete usage protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Pendistrep

This overview summarizes the available research foundation for the combination Benzylpenicillin/Dihydrostreptomycin, including the types of studies conducted, what outcomes researchers focused on, and where regulatory bodies and scientific literature suggest remaining uncertainties exist. The information provided is strictly descriptive and non-advisory.


Evidence for Use in Acute Bacterial Infections in Food-Producing Animals

Research has been studied for conditions involving acute or disruptive episodes of bacterial infections in food-producing animals such as cattle, sheep, and pigs. Controlled clinical trials were evaluated in research exploring the medication’s performance, often using experimental infection models in the target species, to provide data for the regulatory evaluation of this combination. Studies monitored outcomes related to specific pathogens commonly linked to infections such as mastitis.

Studies reported patterns related to the rate of pathogen count reduction measured in the tested populations. Research highlights changes measured during the study period, contributing to the broader evidence landscape.

Scientific literature has explored whether the fixed combination provides a greater pharmacological advantage than a single, appropriate antibiotic; the evidence for this comparison remains limited.


Pharmacokinetic and Bioequivalence Research

Studies also explored the specific drug concentrations achieved in the body, which is a process known as pharmacokinetics. This research examined the absorption and distribution of the two active components using pharmacokinetic (PK) studies. Bioequivalence research explored the measured absorption and distribution of different commercial product formulations.

Research describes the patterns observed in the measured peak concentrations and absorption rates of both components in the animals' systems. This observation highlights that product performance may vary between different commercial formulations.


Evidence Gaps and Areas of Uncertainty

Research describes key limitations identified within the overall evidence base. Comparative evidence that directly measures the incremental pharmacological benefit of the fixed combination over single-agent alternatives remains limited. Certainty remains low regarding the incremental benefit of the combined approach in all scenarios. Limited information exists for long-term outcomes following treatment, and research is ongoing to contextualize these findings within real-world veterinary practice.

Key Studies & References

  1. PROCAINE BENZYLPENICILLIN DIHYDROSTREPTOMYCIN SULFATE - FDA Verification Portal (Regulatory Label/Indications)

Frequently Asked Questions (FAQ)

Common questions about Pendistrep (FAQ)


Q: How quickly should I expect to see an improvement after starting Pendistrep?

A: Pendistrep is designed as a combination of two distinct agents which, according to pharmacological studies, work together to achieve a broad-spectrum and rapid systemic response. This dual action is intended to quickly target susceptible bacteria within the system. Clinical improvement timelines can vary based on the specific infection being addressed.


Q: How long does Pendistrep stay active in the body after the last dose?

A: Official information derived from pharmacokinetic studies examines how the drug's components are absorbed and distributed within the body. The active ingredients, like Dihydrostreptomycin, are generally excreted through the urine. The length of time the components remain in the system is part of the drug's established elimination profile, which varies based on individual factors.


Q: Can Pendistrep cause stomach upset, and is there anything that helps with that?

A: Mild gastrointestinal disturbances are officially classified as a Common Reaction in the drug's safety information. Regulatory documents confirm this side effect but typically do not provide specific guidance on external methods or adjuncts to manage these mild symptoms.


Q: Is it normal to feel a temporary ache or soreness after a Pendistrep injection?

A: Local reactions at the injection site are listed in the official safety profile as a Common Reaction. The classification as a Common Reaction suggests that temporary pain, ache, or soreness immediately following the deep intramuscular injection is a frequently reported event based on documented usage.


Q: Does Pendistrep interact with common birth control methods?

A: For the Benzylpenicillin component, some literature has suggested a potential for interaction with hormonal contraceptives. However, authoritative regulatory guidance for penicillin components often notes that the scientific evidence supporting a significant reduction in the effectiveness of birth control methods is limited or scarce.


Q: Can using Pendistrep for a long time cause any long-term health issues?

A: The established treatment course is typically restricted to a short duration, such as up to 3 consecutive days, which helps to manage risks. Official safety information specifically notes that the risk of a serious side effect called Ototoxicity (which can cause hearing or balance damage) is cumulatively related to the total dose and duration of exposure.


Q: Can people with kidney problems safely use Pendistrep?

A: Regulatory documents establish strict constraints regarding kidney function. Use is considered an absolute contraindication for animals with seriously defective renal function. Official documentation specifies that for cases of pre-existing kidney disease, the product's use is conditional and requires careful monitoring, with established dosage limits.


Q: How should Pendistrep be stored, and does it expire quickly?

A: Official storage instructions state that the product must be kept in a refrigerator (between 2°C and 8°C) and protected from light. It is strictly mandated that the suspension must not be frozen. After the vial is first opened, any remaining product must be used within 28 days and then properly discarded.


Q: Can Pendistrep be used during pregnancy, and are there special considerations?

A: Official warnings note that use in pregnant sows and gilts has been associated with reports of vulval discharge and potential abortion. Furthermore, safety data sheets related to the components sometimes include a hazard statement indicating that the substance is suspected of damaging the unborn child.


Q: What's the difference between Pendistrep and just plain Penicillin?

A: Pendistrep is a combination antibiotic that contains two active ingredients: Benzylpenicillin (a penicillin) and Dihydrostreptomycin (an aminoglycoside). In contrast, plain Penicillin is a single-agent antibiotic that contains only the beta-lactam component.


Q: Is there a generic version of Pendistrep available, and is it the same?

A: The combination of the two active ingredients is commonly known by its generic term, Pen/Strep, which is available under different commercial names. Research into bioequivalence has explored the measured absorption and distribution of these formulations. Research notes that the measured absorption and distribution (pharmacokinetics) may vary between different commercial formulations.


Q: Can Pendistrep be used by people who are allergic to Sulfa drugs?

A: The official contraindications for Pendistrep specifically prohibit its use in individuals with a known history of allergy to penicillins or aminoglycosides. There is no mention in the product's regulatory safety profile of a contraindication related to Sulfa drug allergy.


Q: What specific conditions or infections is Pendistrep typically not effective against?

A: Pendistrep is generally effective against a wide range of susceptible bacteria, including certain Gram-positive and Gram-negative types. However, official product information indicates that the components are not effective against pathogenic fungi and viruses.


Q: What kind of severe, but rare, side effects have been reported with Pendistrep use?

A: The serious adverse reactions associated with this product are classified as rare or uncommon. They include immediate, life-threatening Anaphylactic Shock (related to Benzylpenicillin), as well as potentially irreversible Ototoxicity (damage to the inner ear, causing deafness or vestibular issues) and Acute Renal Failure (Nephrotoxicity), primarily linked to Dihydrostreptomycin.


Q: What is the difference in how Pendistrep works compared to a broad-spectrum antibiotic?

A: Pendistrep is itself classified as a broad-spectrum antimicrobial due to its dual-action mechanism. It achieves this by combining two agents that target distinct, non-overlapping pathways: one component disrupts the cell wall structure, and the other component interferes with protein biosynthesis. This Pathway Synergy provides comprehensive microbial inhibition.


Q: Does Pendistrep have a strong or noticeable smell or taste?

A: Official documentation notes that the product's odor is typically listed as No data available or not specified, as it is an injectable suspension. The product's appearance is described as an off-white/white suspension.


Q: What evidence exists about Pendistrep's potential for developing antibiotic resistance?

A: The use of all antibiotics, including those used in food-producing animals, is closely regulated by government bodies like the FDA due to the global threat of Antimicrobial Resistance (AMR). Regulatory oversight is implemented to help maintain the effectiveness of these antibiotics in both human and animal health, reflecting the concerns over AMR.

How should Pendistrep be stored and disposed of?

Official Storage Requirements

Official regulatory documents stipulate specific environmental controls for storing Pendistrep (Benzylpenicillin/Dihydrostreptomycin injectable suspension) to maintain its stability.

Requirement Condition
Temperature Store in a refrigerator, between 2°C and 8°C.
Protection Must be protected from light and kept in its original outer carton.
Prohibition The product must not be frozen.

Stability and Disposal Rules

Once the vial is opened, the in-use stability period is limited, and specific discard procedures must be followed.

  • Post-Opening Use: The suspension must be used within 28 days following the first dose withdrawal, after which any remaining material must be discarded.
  • Child Safety: It is strictly mandated to keep the product out of the sight and reach of children.
  • Disposal: Unused medicine and waste must not be disposed of via household waste or wastewater. Disposal should be carried out according to official guidance from the local waste regulation authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pendistrep found in:

A-Z Index: